{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:03Z","timestamp":1772166363059,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Division of Nuclear Medicine and Molecular Imaging"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-04-1-0595"],"award-info":[{"award-number":["W81XWH-04-1-0595"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0017"],"award-info":[{"award-number":["W81XWH-15-1-0017"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02188-2","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:03:58Z","timestamp":1768370638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRY\u03b2B2 is a biomarker for poor prognosis and response to CDK4\/6 inhibitors in breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Yu","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athira","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzieh","family":"Mazinani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabi","family":"Lofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine M.","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Afsari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammey","family":"Naab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saraswati","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa F.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2188_CR1","doi-asserted-by":"publisher","first-page":"175883591878645","DOI":"10.1177\/1758835918786451","volume":"10","author":"S Pernas","year":"2018","unstructured":"Pernas S, Tolaney SM, Winer EP, Goel S. CDK4\/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018;10:1758835918786451.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"2188_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2188_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-19-0253","volume":"19","author":"SF Schoninger","year":"2020","unstructured":"Schoninger SF, Blain SW. The ongoing search for biomarkers of CDK4\/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 2020;19(1):3\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"2188_CR4","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4161\/cc.21195","volume":"11","author":"JL Dean","year":"2012","unstructured":"Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11(14):2756\u201361.","journal-title":"Cell Cycle"},{"issue":"7","key":"2188_CR5","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ajpath.2016.02.024","volume":"186","author":"C Karakas","year":"2016","unstructured":"Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, et al. Cytoplasmic cyclin E and phospho-cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer. Am J Pathol. 2016;186(7):1900\u201312.","journal-title":"Am J Pathol"},{"key":"2188_CR6","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61\u201370.","DOI":"10.1038\/nature11412"},{"issue":"18","key":"2188_CR7","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, et al. Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23(18):5561\u201372.","journal-title":"Clin Cancer Res"},{"key":"2188_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-020-0160-4","volume":"6","author":"JM Patel","year":"2020","unstructured":"Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, et al. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020;6:19.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2188_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000455821","volume":"12","author":"E Andreopoulou","year":"2017","unstructured":"Andreopoulou E, Kelly CM, McDaid HM. Therapeutic advances and new directions for triple-negative breast cancer. Breast Care. 2017;12(1):21\u20138.","journal-title":"Breast Care"},{"key":"2188_CR10","doi-asserted-by":"crossref","unstructured":"Yan Y, Narayan A, Cho S, Cheng Z, Liu JO, Zhu H, Wang G, Wharram B, Lisok A, Brummet M et al: CRYbetaB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. Oncogene 2021.","DOI":"10.1038\/s41388-021-01975-3"},{"issue":"12","key":"2188_CR11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.15537\/smj.2016.12.15972","volume":"37","author":"Z Chen","year":"2016","unstructured":"Chen Z, Xu X. Roles of nucleolin. Focus on cancer and anti-cancer therapy. Saudi Med J. 2016;37(12):1312\u20138.","journal-title":"Saudi Med J"},{"issue":"7","key":"2188_CR12","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-07-5723","volume":"68","author":"S Soundararajan","year":"2008","unstructured":"Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358\u201365.","journal-title":"Cancer Res"},{"issue":"2\u20133","key":"2188_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1432-1033.1982.tb06989.x","volume":"128","author":"B Bugler","year":"1982","unstructured":"Bugler B, Caizergues-Ferrer M, Bouche G, Bourbon H, Amalric F. Detection and localization of a class of proteins immunologically related to a 100-kDa nucleolar protein. Eur J Biochem. 1982;128(2\u20133):475\u201380.","journal-title":"Eur J Biochem"},{"issue":"50","key":"2188_CR14","doi-asserted-by":"publisher","first-page":"43370","DOI":"10.1074\/jbc.M111.225185","volume":"286","author":"A Yang","year":"2011","unstructured":"Yang A, Shi G, Zhou C, Lu R, Li H, Sun L, et al. Nucleolin maintains embryonic stem cell self-renewal by suppression of p53 protein-dependent pathway. J Biol Chem. 2011;286(50):43370\u201382.","journal-title":"J Biol Chem"},{"issue":"8","key":"2188_CR15","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41375-018-0090-4","volume":"32","author":"C Mahotka","year":"2018","unstructured":"Mahotka C, Bhatia S, Kollet J, Grinstein E. Nucleolin promotes execution of the hematopoietic stem cell gene expression program. Leukemia. 2018;32(8):1865\u20138.","journal-title":"Leukemia"},{"key":"2188_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.biomaterials.2015.08.007","volume":"69","author":"NA Fonseca","year":"2015","unstructured":"Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregorio AC, Valerio-Fernandes A, et al. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials. 2015;69:76\u201388.","journal-title":"Biomaterials"},{"issue":"1","key":"2188_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","volume":"32","author":"JE Rosenberg","year":"2014","unstructured":"Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014;32(1):178\u201387.","journal-title":"Invest New Drugs"},{"key":"2188_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100390","author":"F Nguyen Van Long","year":"2018","unstructured":"Nguyen Van Long F, Lardy-Cleaud A, Bray S, Chabaud S, Dubois T, Diot A, et al. Druggable nucleolin identifies breast tumours associated with poor prognosis that exhibit different biological processes. Cancers. 2018. https:\/\/doi.org\/10.3390\/cancers10100390.","journal-title":"Cancers"},{"issue":"1","key":"2188_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-012-0827-2","volume":"108","author":"Z Xu","year":"2012","unstructured":"Xu Z, Joshi N, Agarwal A, Dahiya S, Bittner P, Smith E, et al. Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. J Neurooncol. 2012;108(1):59\u201367.","journal-title":"J Neurooncol"},{"issue":"52","key":"2188_CR20","doi-asserted-by":"publisher","first-page":"33327","DOI":"10.1074\/jbc.272.52.33327","volume":"272","author":"B Sarcevic","year":"1997","unstructured":"Sarcevic B, Lilischkis R, Sutherland RL. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem. 1997;272(52):33327\u201337.","journal-title":"J Biol Chem"},{"issue":"1","key":"2188_CR21","first-page":"590","volume":"41","author":"F Huang","year":"2019","unstructured":"Huang F, Wu Y, Tan H, Guo T, Zhang K, Li D, et al. Phosphorylation of nucleolin is indispensable to its involvement in the proliferation and migration of non-small cell lung cancer cells. Oncol Rep. 2019;41(1):590\u20138.","journal-title":"Oncol Rep"},{"issue":"16","key":"2188_CR22","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1093\/nar\/17.16.6625","volume":"17","author":"P Belenguer","year":"1989","unstructured":"Belenguer P, Baldin V, Mathieu C, Prats H, Bensaid M, Bouche G, et al. Protein kinase NII and the regulation of rDNA transcription in mammalian cells. Nucleic Acids Res. 1989;17(16):6625\u201336.","journal-title":"Nucleic Acids Res"},{"issue":"31","key":"2188_CR23","doi-asserted-by":"publisher","first-page":"22223","DOI":"10.1074\/jbc.M513335200","volume":"281","author":"E Grinstein","year":"2006","unstructured":"Grinstein E, Shan Y, Karawajew L, Snijders PJ, Meijer CJ, Royer HD, et al. Cell cycle-controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation. J Biol Chem. 2006;281(31):22223\u201335.","journal-title":"J Biol Chem"},{"issue":"1","key":"2188_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2005.07.034","volume":"123","author":"M Takagi","year":"2005","unstructured":"Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005;123(1):49\u201363.","journal-title":"Cell"},{"issue":"2","key":"2188_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199\u2013212.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2188_CR26","first-page":"313","volume":"148","author":"PJ Dawson","year":"1996","unstructured":"Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148(1):313\u20139.","journal-title":"Am J Pathol"},{"issue":"43","key":"2188_CR27","doi-asserted-by":"publisher","first-page":"17773","DOI":"10.1073\/pnas.1110969108","volume":"108","author":"H Konishi","year":"2011","unstructured":"Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011;108(43):17773\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"2188_CR28","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/onc.2010.220","volume":"29","author":"MB Weiss","year":"2010","unstructured":"Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, et al. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 2010;29(33):4715\u201324.","journal-title":"Oncogene"},{"issue":"37","key":"2188_CR29","doi-asserted-by":"publisher","first-page":"11583","DOI":"10.1073\/pnas.1503683112","volume":"112","author":"S Croessmann","year":"2015","unstructured":"Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, et al. NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proc Natl Acad Sci U S A. 2015;112(37):11583\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2188_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2188_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01320-8","volume":"22","author":"NA O'Brien","year":"2020","unstructured":"O\u2019Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, et al. Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020;22(1):89.","journal-title":"Breast Cancer Res"},{"issue":"5 Pt B","key":"2188_CR32","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.bbagen.2016.12.015","volume":"1861","author":"PJ Bates","year":"2017","unstructured":"Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O\u2019Toole MG, Trent JO. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. Biochimica et Biophysica Acta (BBA). 2017;1861(5 Pt B):1414\u201328.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"4","key":"2188_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339.","journal-title":"Lancet Oncol"},{"key":"2188_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918818346","volume":"10","author":"A Matutino","year":"2018","unstructured":"Matutino A, Amaro C, Verma S. CDK4\/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Ther Adv Med Oncol. 2018;10:1758835918818346.","journal-title":"Ther Adv Med Oncol"},{"key":"2188_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-8-66","volume":"8","author":"I Ugrinova","year":"2007","unstructured":"Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8:66.","journal-title":"BMC Mol Biol"},{"issue":"1","key":"2188_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbrc.2014.09.049","volume":"453","author":"Q Gao","year":"2014","unstructured":"Gao Q, Sun LL, Xiang FF, Gao L, Jia Y, Zhang JR, et al. Crybb2 deficiency impairs fertility in female mice. Biochem Biophys Res Commun. 2014;453(1):37\u201342.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"2188_CR37","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/0008-5472.CAN-15-1619","volume":"76","author":"VF Merino","year":"2016","unstructured":"Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, et al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer. Cancer Res. 2016;76(7):2013\u201324.","journal-title":"Cancer Res"},{"issue":"1","key":"2188_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13058-018-1068-x","volume":"20","author":"VF Merino","year":"2018","unstructured":"Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C Jr, et al. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Res BCR. 2018;20(1):145.","journal-title":"Breast Cancer Res BCR"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02188-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:59:48Z","timestamp":1770721188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2188"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02188-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6431382\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}